HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GENFLEET-B

28.160

-3.900-12.16%

Volume:6.59M

Turnover:191.35M

Market Cap:10.79B

PE:-4.64

High:32.900

Open:31.600

Low:27.740

Close:32.060

52wk High:52.900

52wk Low:19.600

Shares:383.00M

HK Float Shares:351.00M

Volume Ratio:4.51

T/O Rate:1.88%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-6.070

ROE:--

ROA:-19.54%

PB:5.74

PE(LYR):-4.64

PS:109.68

Loading ...

Overview Company News Filings

GenFleet Therapeutics Lung Cancer Drug Candidate Enters Phase 2 Trial

MT Newswires Live

HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off

GenFleet Pushes Lead KRAS G12D Candidate GFH375 into China Phase II First-Line NSCLC Trial, Testing Monotherapy and Combos with Cetuximab or Pemetrexed

Bulletin Express

Genfleet Therapeutics (Shanghai) - Gfh375 Enters Phase Ii Study for First-Line Kras G12d-Mutant Nsclc

THOMSON REUTERS

GenFleet Therapeutics (Shanghai) Reports Loss of Rmb220.17 Million for Six Months

GenFleet 1H26 Net Loss Narrows 68.5% to RMB220 Million as Other Income Surges, Cash Pile at RMB1.78 Billion

Bulletin Express

Genfleet Therapeutics (Shanghai) - Reports Loss of Rmb220.17 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS

Genfleet Therapeutics (Shanghai) - Reports Revenue of Rmb42.47 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS

GenFleet Interim Loss Narrows to RMB 220.17 Million in FY26 H1; Revenue Falls to RMB 42.47 Million

GENFLEET-B Advances Two First-in-Class Pancreatic Cancer Combination Therapies into Phase II Trials

GenFleet Starts Phase II Trial of KRAS G12D Inhibitor Gfh375 Combos in Pretreated Pancreatic Cancer Patients

GENFLEET-B: Wellington Management Group LLP Acquires Shares, Long Position Rises to 7.0%

Earning Preview: GENFLEET-B revenue outlook hinges on milestone timing as institutions remain cautious

GenFleet Therapeutics's Lung Cancer Drug Advances in Phase 3 Trial, First Patient Dosed

MT Newswires Live

GenFleet Rises Most in 4 Weeks on Progress of Gfh375 in Cancer Treatment

GenFleet Doses First Patient in China Phase III Trial of KRAS G12D Inhibitor Gfh375 for NSCLC

Genfleet Therapeutics (Shanghai) - Gfh375 Advances to Registrational Phase Iii Study in China for Kras G12d-Mutant Nsclc

THOMSON REUTERS

GenFleet Therapeutics to Hold Board Meeting on Interim Results, Dividend Recommendation

GenFleet Therapeutics Sets 21 Aug 2026 Board Meeting to Approve H1 2026 Interim Results and Dividend Plan

Bulletin Express

GenFleet Therapeutics Issues 13.60 Million New H Shares via HK$34.69 Placing, Lifts Total Issued Shares to 351.63 Million

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02595/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"GENFLEET-B","latestPrice":28.16,"timestamp":1791446897006,"preClose":32.06,"halted":0,"volume":6586200,"delay":0,"changeRate":-0.1216469120399252,"floatShares":351000000,"shares":383000000,"eps":-6.07,"marketStatus":"Not Yet Opened","change":-3.9,"latestTime":"10-08 16:08:17","open":31.6,"high":32.9,"low":27.74,"amount":191349457,"amplitude":0.160948,"askPrice":28.16,"askSize":9000,"bidPrice":28.12,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-3.946,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791509400000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":32.06,"openAndCloseTimeList":[[1791423000000,1791432000000],[1791435600000,1791446400000]],"volumeRatio":4.50988,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":351000000,"roa":"-19.54%","roe":"--","lyrEps":-6.07,"volumeRatio":4.50988,"shares":383000000,"dividePrice":0,"high":32.9,"amplitude":0.160948,"preClose":32.06,"low":27.74,"week52Low":19.6,"pbRate":"5.74","psRate":"109.68","week52High":52.9,"institutionHeld":0,"latestPrice":28.16,"committee":-0.875,"eps":-6.07,"divideRate":0,"volume":6586200,"delay":0,"ttmEps":-3.946,"open":31.6,"prevYearClose":23.78,"prevWeekClose":31.94,"prevMonthClose":33,"prevQuarterClose":33,"fiveDayClose":33,"twentyDayClose":26.3,"sixtyDayClose":42.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[{"date":"2026-08-21","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787275800000,"name":null,"time":"","dateTimestamp":1787241600000,"actualEps":null},{"date":"2026-03-24","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774315800000,"name":null,"time":"","dateTimestamp":1774281600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1788105600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2026-10-07","current":-7.136341,"percent":0.682353,"low":-19.62221,"twenty":-10.688438,"median":-9.045193,"eighty":-7.05968,"high":-5.69787,"avg":-9.246376,"sd":2.656034,"marketCap":11873954157},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-21","current":-10.329745,"twenty":-18.396816,"median":-10.725216,"eighty":-10.005136,"marketCap":10481375629},{"date":"2025-11-28","current":-10.423287,"twenty":-18.142029,"median":-10.678396,"eighty":-10.044836,"marketCap":10614707615},{"date":"2025-12-05","current":-10.100425,"twenty":-16.087956,"median":-10.631034,"eighty":-10.044836,"marketCap":10303599646},{"date":"2025-12-12","current":-10.212238,"twenty":-13.008301,"median":-10.584309,"eighty":-10.020393,"marketCap":10436931633},{"date":"2025-12-19","current":-9.790532,"twenty":-12.136764,"median":-10.450758,"eighty":-9.957409,"marketCap":10029528340},{"date":"2025-12-24","current":-8.945585,"twenty":-11.809112,"median":-10.416014,"eighty":-9.900509,"marketCap":9192499756},{"date":"2026-01-02","current":-8.020182,"twenty":-11.73453,"median":-10.320373,"eighty":-9.861601,"marketCap":8273990514},{"date":"2026-01-09","current":-11.588563,"twenty":-11.683046,"median":-10.309663,"eighty":-9.776189,"marketCap":11985064146},{"date":"2026-01-16","current":-11.693807,"twenty":-11.67863,"median":-10.369243,"eighty":-9.793132,"marketCap":12133210798},{"date":"2026-01-23","current":-10.361602,"twenty":-11.605818,"median":-10.329745,"eighty":-9.783265,"marketCap":10740632270},{"date":"2026-01-30","current":-10.919089,"twenty":-11.483053,"median":-10.385171,"eighty":-9.793132,"marketCap":11370255541},{"date":"2026-02-06","current":-11.146899,"twenty":-11.598147,"median":-10.450758,"eighty":-9.8258,"marketCap":11636919514},{"date":"2026-02-13","current":-10.659945,"twenty":-11.483053,"median":-10.58187,"eighty":-9.869606,"marketCap":11192479558},{"date":"2026-02-20","current":-10.145441,"twenty":-11.446311,"median":-10.573435,"eighty":-9.881527,"marketCap":10636929613},{"date":"2026-02-27","current":-9.574146,"twenty":-11.38719,"median":-10.509847,"eighty":-9.836956,"marketCap":10148045662},{"date":"2026-03-06","current":-8.841756,"twenty":-11.29428,"median":-10.416014,"eighty":-9.744297,"marketCap":9296202413},{"date":"2026-03-13","current":-10.316011,"twenty":-11.38719,"median":-10.450758,"eighty":-9.761464,"marketCap":10896186254},{"date":"2026-03-20","current":-10.186272,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"marketCap":10718410272},{"date":"2026-03-27","current":-5.945762,"twenty":-11.270982,"median":-10.329745,"eighty":-9.723416,"marketCap":12081359470},{"date":"2026-04-02","current":-6.621163,"twenty":-11.205287,"median":-10.312136,"eighty":-9.574146,"marketCap":13518381995},{"date":"2026-04-10","current":-7.067323,"twenty":-11.18954,"median":-10.310332,"eighty":-9.547859,"marketCap":14540593893},{"date":"2026-04-17","current":-8.194366,"twenty":-11.170082,"median":-10.271344,"eighty":-9.114302,"marketCap":16866496330},{"date":"2026-04-24","current":-11.736244,"twenty":-11.170082,"median":-10.248784,"eighty":-8.950161,"marketCap":18318333519},{"date":"2026-04-30","current":-10.233962,"twenty":-11.173069,"median":-10.230093,"eighty":-8.995356,"marketCap":15977616418},{"date":"2026-05-08","current":-9.881779,"twenty":-11.158327,"median":-10.186272,"eighty":-9.095725,"marketCap":15481325134},{"date":"2026-05-15","current":-8.422278,"twenty":-11.148553,"median":-10.161068,"eighty":-8.948635,"marketCap":13229496023},{"date":"2026-05-22","current":-7.916926,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"marketCap":12407282105},{"date":"2026-05-29","current":-8.035507,"twenty":-11.019944,"median":-10.082937,"eighty":-8.624127,"marketCap":12636909415},{"date":"2026-06-05","current":-6.909175,"twenty":-10.994143,"median":-10.039967,"eighty":-8.441141,"marketCap":10881371589},{"date":"2026-06-12","current":-6.584396,"twenty":-10.981505,"median":-9.989391,"eighty":-8.291507,"marketCap":10362858307},{"date":"2026-06-18","current":-6.718884,"twenty":-10.969649,"median":-9.941921,"eighty":-8.193596,"marketCap":10599892950},{"date":"2026-06-26","current":-5.732708,"twenty":-10.937065,"median":-9.927249,"eighty":-8.035507,"marketCap":8999909109},{"date":"2026-07-03","current":-7.180567,"twenty":-10.922684,"median":-9.900616,"eighty":-7.915515,"marketCap":11281367549},{"date":"2026-07-10","current":-9.054005,"twenty":-10.894174,"median":-9.893411,"eighty":-7.915515,"marketCap":14207263926},{"date":"2026-07-17","current":-8.396292,"twenty":-10.887172,"median":-9.884317,"eighty":-7.956496,"marketCap":13222088691},{"date":"2026-07-24","current":-8.187485,"twenty":-10.884642,"median":-9.862553,"eighty":-8.009423,"marketCap":12896166056},{"date":"2026-07-31","current":-6.510345,"twenty":-10.870773,"median":-9.833804,"eighty":-7.907869,"marketCap":10273970316},{"date":"2026-08-07","current":-7.003679,"twenty":-10.846908,"median":-9.792157,"eighty":-7.575355,"marketCap":11073962237},{"date":"2026-08-14","current":-7.214728,"twenty":-10.805358,"median":-9.754197,"eighty":-7.296139,"marketCap":11422106869},{"date":"2026-08-21","current":-7.917767,"twenty":-10.771121,"median":-9.6954,"eighty":-7.255608,"marketCap":12562836089},{"date":"2026-08-28","current":-7.346545,"twenty":-10.748709,"median":-9.635917,"eighty":-7.293508,"marketCap":11659141512},{"date":"2026-09-04","current":-6.41515,"twenty":-10.730984,"median":-9.570725,"eighty":-7.1768,"marketCap":10185082325},{"date":"2026-09-11","current":-5.935917,"twenty":-10.723237,"median":-9.522333,"eighty":-7.102704,"marketCap":9436941732},{"date":"2026-09-18","current":-6.230255,"twenty":-10.708658,"median":-9.391188,"eighty":-7.03728,"marketCap":9592495717},{"date":"2026-09-25","current":-7.20619,"twenty":-10.699734,"median":-9.151454,"eighty":-7.03728,"marketCap":11073962237},{"date":"2026-10-02","current":-7.689742,"twenty":-10.695182,"median":-9.058573,"eighty":-7.026079,"marketCap":11829510162},{"date":"2026-10-07","current":-7.707627,"twenty":-10.688438,"median":-9.045193,"eighty":-7.05968,"marketCap":11873954157}],"updateTime":1791486113626},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662798913","title":"GenFleet Therapeutics Lung Cancer Drug Candidate Enters Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662798913","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662798913?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:55","pubTimestamp":1787727342,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics  said GFH375 entered a phase II study for first-line treatment of patients with non-small cell lung cancer.The trial will be conducted in a number of clinical sites across China, with Guangdong Provincial People's Hospital as the leading site, according to a Wednesday Hong Kong bourse filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","BK4539","BK1161","02595","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115078027","title":"HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1115078027","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115078027?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:17","pubTimestamp":1787707028,"startTime":"0","endTime":"0","summary":"Key corporate developments this week: GenFleet Therapeutics-B (02595) has initiated a Phase II study evaluating GFH375, an oral KRAS G12D inhibitor, as a first-line treatment for non-small cell lung...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","02595","BK1574","IE00B543WZ88.USD","KCAI","LU0348827113.USD","LU2476274308.USD","LU2488822045.USD","BK1586","LU2778985437.USD","BK1161","KURE","LU2476274720.SGD","BK4588","LU0417516571.SGD","LU0417516738.SGD","LU0634319403.HKD","BK1237","LU0348735423.USD","LU0417516902.SGD","LU0348825331.USD","BK1526","BK4585","LU0540923850.HKD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0348783233.USD","LU0348766576.USD","LU0348767384.USD","LU1794554557.SGD","00354","LU1720050803.USD","VXUS","LU0348784397.USD","09926","00660","BK1518","BK1589","LU1961090484.USD","BK1155","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151749730","title":"GenFleet Pushes Lead KRAS G12D Candidate GFH375 into China Phase II First-Line NSCLC Trial, Testing Monotherapy and Combos with Cetuximab or Pemetrexed","url":"https://stock-news.laohu8.com/highlight/detail?id=1151749730","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151749730?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:06","pubTimestamp":1787702798,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (GenFleet; SEHK: 02595) has initiated a multicenter, open-label, randomized Phase II study to evaluate its oral KRAS G12D inhibitor GFH375 as a first-line treatment for advanced...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662276338","title":"Genfleet Therapeutics (Shanghai) - Gfh375 Enters Phase Ii Study for First-Line Kras G12d-Mutant Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2662276338","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662276338?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:00","pubTimestamp":1787702457,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44M0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661726566","title":"GenFleet Therapeutics (Shanghai) Reports Loss of Rmb220.17 Million for Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2661726566","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661726566?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:44","pubTimestamp":1787301897,"startTime":"0","endTime":"0","summary":"BRIEF-GenFleet Therapeutics  Reports Loss Of RMB220.17 Million For Six MonthsAug 21 -GenFleet Therapeutics  Inc2595.HK:REPORTS REVENUE OF RMB42.47 MILLION FOR SIX MONTHS ENDED JUNE 30, 2026REPORTS LOSS OF RMB220.17 MILLION FOR SIX MONTHS ENDED JUNE 30, 2026Further company coverage:2595.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161579224","title":"GenFleet 1H26 Net Loss Narrows 68.5% to RMB220 Million as Other Income Surges, Cash Pile at RMB1.78 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1161579224","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161579224?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:07","pubTimestamp":1787285225,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. (GenFleet) released unaudited interim results for the six months ended 30 June 2026, showing a significantly reduced net loss and strengthened liquidity despite...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GenFleet 1H26 Net Loss Narrows 68.5% to RMB220 Million as Other Income Surges, Cash Pile at RMB1.78 Billion","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661405251","title":"Genfleet Therapeutics (Shanghai) - Reports Loss of Rmb220.17 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661405251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661405251?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:02","pubTimestamp":1787284948,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1I7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661251403","title":"Genfleet Therapeutics (Shanghai) - Reports Revenue of Rmb42.47 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661251403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661251403?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:02","pubTimestamp":1787284948,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661514082","title":"GenFleet Interim Loss Narrows to RMB 220.17 Million in FY26 H1; Revenue Falls to RMB 42.47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661514082","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661514082?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:01","pubTimestamp":1787284885,"startTime":"0","endTime":"0","summary":"GenFleet interim loss narrows to RMB 220.17 million in FY26 H1; revenue falls to RMB 42.47 millionGenFleet Therapeutics posted a net loss of RMB 220.17 million for the six months ended June 30, 2026, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL2V87Ps:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193023804","title":"GENFLEET-B Advances Two First-in-Class Pancreatic Cancer Combination Therapies into Phase II Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1193023804","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193023804?lang=en_us&edition=fundamental","pubTime":"2026-08-20 08:16","pubTimestamp":1787184978,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) has announced the initiation of a three-arm, parallel-controlled Phase II clinical study evaluating GFH375, an oral KRAS G12D ON/OFF inhibitor. The trial will assess two novel...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159938","09939","02595","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660790224","title":"GenFleet Starts Phase II Trial of KRAS G12D Inhibitor Gfh375 Combos in Pretreated Pancreatic Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2660790224","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660790224?lang=en_us&edition=fundamental","pubTime":"2026-08-20 08:01","pubTimestamp":1787184103,"startTime":"0","endTime":"0","summary":"GenFleet starts Phase II trial of KRAS G12D inhibitor GFH375 combos in pretreated pancreatic cancer patientsGenFleet launched a three-arm Phase II trial in China for GFH375 in pretreated KRAS G12D-mut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4NfWjt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103027770","title":"GENFLEET-B: Wellington Management Group LLP Acquires Shares, Long Position Rises to 7.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103027770","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103027770?lang=en_us&edition=fundamental","pubTime":"2026-08-17 17:12","pubTimestamp":1786957929,"startTime":"0","endTime":"0","summary":"On August 13, 2026, Wellington Management Group LLP bought 28,800 shares of GENFLEET-B (02595) (H shares) at an average of HKD 31.4819 per share, involving about HKD 906,679.Prior to the acquisition,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178800304","title":"Earning Preview: GENFLEET-B revenue outlook hinges on milestone timing as institutions remain cautious","url":"https://stock-news.laohu8.com/highlight/detail?id=1178800304","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178800304?lang=en_us&edition=fundamental","pubTime":"2026-08-14 09:34","pubTimestamp":1786671240,"startTime":"0","endTime":"0","summary":"Abstract GenFleet Therapeutics (Shanghai) Inc. will report quarterly results on August 21, 2026 post-Market; the update will likely center on margin resilience versus expanding R&D investment, with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: GENFLEET-B revenue outlook hinges on milestone timing as institutions remain cautious","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658437984","title":"GenFleet Therapeutics's Lung Cancer Drug Advances in Phase 3 Trial, First Patient Dosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2658437984","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658437984?lang=en_us&edition=fundamental","pubTime":"2026-08-10 17:31","pubTimestamp":1786354309,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics 's  GFH375 advanced into a registrational phase III study in China, according to a Monday Hong Kong bourse filing.The trial will be conducted across over 40 sites nationwide, with the first patient recently dosed at Nanjing Drum Tower Hospital.The trial will evaluate monotherapy efficacy and safety versus docetaxel in patients with KRAS G12D-mutant locally advanced, unresectable, or metastatic non-small cell lung cancer who have failed standard-of-care therapy.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK1161","02595","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658985346","title":"GenFleet Rises Most in 4 Weeks on Progress of Gfh375 in Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658985346","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658985346?lang=en_us&edition=fundamental","pubTime":"2026-08-10 15:21","pubTimestamp":1786346506,"startTime":"0","endTime":"0","summary":"BUZZ-GenFleet rises most in 4 weeks on progress of GFH375 in cancer treatment** Shares of GenFleet Therapeutics  Inc2595.HKrise 8.6% to HK$32.48, on course for their biggest one-day pct gain since July 15** Stock hits the highest point since July 28 in the fifth consecutive session of gain** China-based innovative drugs developer said its oral KRAS G12D inhibitorGFH375for cancer treatment has advanced into a multicenter, open-label, randomized controlled registrational phase III study in China for evaluating monotherapy efficacy and safety** YTD, stock up 34.4%, Hang Seng Biotech Index.HSBIOup 9%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N44705M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658056066","title":"GenFleet Doses First Patient in China Phase III Trial of KRAS G12D Inhibitor Gfh375 for NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658056066","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658056066?lang=en_us&edition=fundamental","pubTime":"2026-08-10 08:01","pubTimestamp":1786320110,"startTime":"0","endTime":"0","summary":"GenFleet doses first patient in China Phase III trial of KRAS G12D inhibitor GFH375 for NSCLCGenFleet started a registrational Phase III China trial of oral KRAS G12D inhibitor GFH375 in previously tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL50jB2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605675","title":"Genfleet Therapeutics (Shanghai) - Gfh375 Advances to Registrational Phase Iii Study in China for Kras G12d-Mutant Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658605675?lang=en_us&edition=fundamental","pubTime":"2026-08-10 08:01","pubTimestamp":1786320088,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4450BY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572308","title":"GenFleet Therapeutics to Hold Board Meeting on Interim Results, Dividend Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572308","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572308?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:05","pubTimestamp":1785971114,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics to hold board meeting on interim results, dividend recommendationGenfleet Therapeutics schedules a board meeting for Aug. 21, 2026 to review interim results for the six months en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL6CxlVg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124539406","title":"GenFleet Therapeutics Sets 21 Aug 2026 Board Meeting to Approve H1 2026 Interim Results and Dividend Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124539406","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124539406?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:08","pubTimestamp":1785967687,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. announced that its board of directors will convene on 21 August 2026. The meeting agenda includes: • Reviewing and approving the consolidated interim results for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111499452","title":"GenFleet Therapeutics Issues 13.60 Million New H Shares via HK$34.69 Placing, Lifts Total Issued Shares to 351.63 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1111499452","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111499452?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:29","pubTimestamp":1785922141,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. completed the allotment of 13.60 million new H shares on 17 July 2026 at HK$34.69 per share under a general mandate, according to the company’s Monthly Return...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":131,"code":"91000000","status":"200"}]}}